遗传性血管与正常C1酶抑制剂:当前的范式和临床困境
Cristine Radojicic1, John Anderson2
1From the Division of Pulmonary, Allergy and Critical Care, Department of Medicine, Duke University, Durham, North Carolina.
Allergy and asthma proceedings
|May 17, 2024
概括
通过正常的C1酶抑制剂 (HAE-nl-C1-INH) 诊断遗传性血管是具有挑战性的. 管理包括在考虑HAE类型I/II治疗之前排除乳腺细胞通路.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 与正常C1酶抑制剂 (HAE-nl-C1-INH) 相结合的遗传性血管炎带来了诊断和治疗方面的挑战.
- 症状与其他HAE类型重叠,使诊断复杂化.
研究的目的:
- 讨论HAE-nl-C1-INH.INH的实际管理方面的考虑.
- 用临床图片突出显示诊断和治疗方面的挑战.
主要方法:
- 临床管理策略的叙述性审查.
- 对诊断标准和治疗方法的分析.
主要成果:
- 诊断方面的挑战包括症状异质性和缺乏特定生物标志物.
- 建议采取逐步的方法:首先,研究杆细胞向治疗方法,然后考虑HAE类型I/II指南.
- 对HAE类型I/II药物的反应支持HAE-nl-C1-INH诊断.
结论:
- 关键的未满足需求包括确认诊断生物标志物和对HAE-nl-C1-INH的受控临床研究.
- 准确的诊断和删除标签标准对于患者护理至关重要.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
620
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
620
Antihypertensive Drugs: Direct Renin Inhibitors
601
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
601
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Angle Closure Glaucoma: Treatment
480
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
480
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157


